113 related articles for article (PubMed ID: 35189054)
1. Screening of V617F mutation in JAK2 gene with acute myeloid leukemia in the Saudi population.
Farasani A
Acta Biochim Pol; 2022 Feb; 69(1):211-214. PubMed ID: 35189054
[TBL] [Abstract][Full Text] [Related]
2. Morphologic and Molecular Characteristics of De Novo AML With
Hidalgo-López JE; Kanagal-Shamanna R; Medeiros LJ; Estrov Z; Yin CC; Verstovsek S; Konoplev S; Jorgensen JL; Mohammad MM; Miranda RN; Zhao C; Lee J; Zuo Z; Bueso-Ramos CE
J Natl Compr Canc Netw; 2017 Jun; 15(6):790-796. PubMed ID: 28596259
[No Abstract] [Full Text] [Related]
3. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
Li WY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
[TBL] [Abstract][Full Text] [Related]
5. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.
Illmer T; Schaich M; Ehninger G; Thiede C;
Haematologica; 2007 Jan; 92(1):137-8. PubMed ID: 17229652
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
10. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
11. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
[TBL] [Abstract][Full Text] [Related]
12. [Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):866-9. PubMed ID: 19698218
[TBL] [Abstract][Full Text] [Related]
13. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
15. JAK2V617F mutations in myeloid malignancies: single center experience.
Panovska-Stavridis I; Cevreska L; Ivanovski M; Stojanovik A; Lozance M; Matevska N; Dimovski A; Serafimoski V
Prilozi; 2008 Dec; 29(2):257-67. PubMed ID: 19259051
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
[TBL] [Abstract][Full Text] [Related]
17. Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with JAK2 V617F mutation.
Swaminathan S; Madkaikar M; Ghosh K; Vundinti BR; Kerketta L; Gupta M
Eur J Haematol; 2010 Feb; 84(2):180-2. PubMed ID: 19824900
[No Abstract] [Full Text] [Related]
18. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
Theocharides A; Boissinot M; Girodon F; Garand R; Teo SS; Lippert E; Talmant P; Tichelli A; Hermouet S; Skoda RC
Blood; 2007 Jul; 110(1):375-9. PubMed ID: 17363731
[TBL] [Abstract][Full Text] [Related]
19. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
20. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
Roug AS; Nyvold CG; Juhl-Christensen C; Christensen M; Schnittger S; Hokland P
Eur J Haematol; 2011 Nov; 87(5):461-3. PubMed ID: 21689158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
